ArticleJCEM case reports2026
Late-onset autoimmune diabetes in 2 octogenarians: diagnostic misclassification and therapeutic heterogeneity.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Latent autoimmune diabetes in adults (LADA) may be misclassified as type 2 diabetes mellitus (T2DM) and remain unrecognized without targeted evaluation. We describe 2 octogenarians with LADA initially managed as T2DM. The first, an 84-year-old man with chronic kidney disease and normal body mass index, developed glycemic variability with hypoglycemia on multiple daily insulin injections and was intolerant of noninsulin therapies. Evaluation revealed positive pancreatic autoantibodies and preserved C-peptide of 5.68 ng/mL (SI: 1.89 nmol/L) (reference range, 1.1-5.5 ng/mL [SI: 0.37-1.83 nmol/L]). Following transition to automated insulin delivery (AID), time in range (TIR; glucose 70-180 mg/dL [SI: 3.9-10.0 mmol/L]) improved from 33% to 75% and glucose management indicator (GMI) from 8.4% (SI: 68 mmol/mol; targets individualized) to 7.0% (SI: 53 mmol/mol), within 1 month, sustained at 6 months without hypoglycemia. The second, an 80-year-old woman receiving insulin and metformin, developed hypoglycemia; evaluation showed positive pancreatic autoantibodies and preserved C-peptide (1.6 ng/mL [SI: 0.53 nmol/L]). She underwent treatment de-escalation, achieving control on metformin alone with 77% TIR and GMI of 7.0% (SI: 53 mmol/mol) at 1 month, sustained at 3 months without hypoglycemia. These cases highlight preserved endogenous insulin secretion and therapeutic heterogeneity in LADA, requiring individualized management, including AID.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.